MEDICLIN AG
ISIN: DE0006595101
WKN: 659510
04 November 2025 02:13PM

EQS-News: MEDICLIN on track: business development in line with expectations

MEDICLIN AG · ISIN: DE0006595101 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 2223588

EQS-News: MEDICLIN AG / Key word(s): 9 Month figures/Miscellaneous
MEDICLIN on track: business development in line with expectations

04.11.2025 / 14:13 CET/CEST
The issuer is solely responsible for the content of this announcement.


Offenburg, 4 November 2025
MEDICLIN on track: business development in line with expectations
                                                                             
  • Group operating result amounts to EUR 48.9 million (9M 2024: EUR 34.5 million)
  • Consolidated group sales amounts to EUR 586.9 million (9M 2024: EUR 558.2 million)
  • Overall capacity utilisation stable at 86.8%
Offenburg, 4 November 2025: MEDICLIN Aktiengesellschaft (ticker: MED; WKN 659 510) generated consolidated group sales of EUR 586.9 million in the first nine months of 2025. This corresponds to an increase of EUR 28.7 million or 5.1% compared with the same period last year. Group operating result amounted to EUR 48.9 million (9M 2024: EUR 34.5 million). Overall capacity utilisation within the Group remained stable at 86.8% (9M 2024: 86.0%).

Developments in the segments

In the post-acute segment, sales increased by 9.3% to EUR 394.6 million (9M 2024: EUR 361.2 million). Segment operating result rose by EUR 9.6 million to EUR 47.6 million (9M 2024: EUR 38.0 million). The cost of materials ratio fell by 0.9 percentage points to 19.5% (9M 2024: 20.4%). Total cost of materials amounted to EUR 77.0 million, representing an increase of 4.4% compared with the same period of the previous year (9M 2024: EUR 73.8 million). Personnel expenses increased by EUR 17.6 million or 9.4% to EUR 205.0 million, mainly due to salary increases and a higher number of employees. The personnel expense ratio remained unchanged at 51.9%.

Developments in the acute segment were significantly influenced by the sale of the former MEDICLIN Herzzentrum Coswig. Segment sales decreased by EUR 5.7 million or 3.2%.  The cost of materials fell by 4.8% to EUR 47.6 million (9M 2024: EUR 50.0 million). The cost of materials ratio declined slightly to 28.0% (9M 2024: 28.5%). Personnel expenses amounted to EUR 101.0 million, down 4.8% on the previous year (9M 2024: EUR 106.1 million). At 59.4%, the personnel expense ratio was one percentage point below the previous year's level (9M 2024: 60.4%). The segment’s operating result improved by a total of EUR 4.5 million or 117.2% to EUR 0.7 million (9M 2024: EUR –3.8 million).

Sales in the nursing care segment amounted to EUR 18.6 million in the first nine months of 2025 (9M 2024: EUR 17.5 million), while the segment operating result was EUR –0.4 million, down EUR 0.5 million on the same period of the previous year (9M 2024: EUR 0.1 million).

Sales in the service segment increased by EUR 3.3 million to EUR 74.8 million (9M 2024: EUR 71.5 million). At EUR 1.0 million, the segment operating result was EUR 0.8 million higher than in the same period of the previous year (9M 2024: EUR 0.2 million).

Outlook and current events

The Management Board confirms its guidance for the 2025 financial year, with consolidated group sales to grow by between 2.0% and 5.0% and consolidated group EBIT between EUR 53.0 million and EUR 64.0 million.

“In view of the current conditions and typical seasonal effects in the fourth quarter, we continue to assess business development as solid. With the current quarterly results, we are demonstrating that we will achieve our original annual guidance and successfully conclude the current financial year,” comments Tino Fritz, CFO of MEDICLIN.

The interim report as of 30 September 2025 is available in German and English at www.mediclin.de as of today.

For further information:

MEDICLIN Aktiengesellschaft
Okenstraße 27
77652 Offenburg

Investor Relations
Ender Gülcan
Tel.: +49781/488-326
ender.guelcan@mediclin.de



www.mediclin.de


About MEDICLIN Aktiengesellschaft (Ticker: MED; WKN: 659 510)
MEDICLIN includes 31 clinics, six care facilities and nine medical care centers. The group has around 8,200 beds/care places and employs around 9,900 people.
In a strong network, MEDICLIN offers the patients integrative care from the first visit to the doctor through the operation and subsequent rehabilitation to outpatient aftercare. Doctors, therapists and nurses work together in a carefully coordinated manner. MEDICLIN designs the care and support of people in need of care according to their individual needs and personal needs.

MEDICLIN ─ a company of the Asklepios Group

 


04.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: MEDICLIN AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: ender.guelcan@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2223588

 
End of News EQS News Service

2223588  04.11.2025 CET/CEST

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2019 2020 2021 2022 2023 2024 2025e
Sales1 673,09 659,86 673,14 704,70 730,07 748,75 778,00
EBITDA1,2 93,58 77,50 85,22 90,92 98,73 103,77 115,00
EBITDA-Margin3 13,90 11,75 12,66 12,90 13,52 13,86 14,78
EBIT1,4 22,41 0,15 11,56 19,52 12,72 53,49 63,00
EBIT-Margin5 3,33 0,02 1,72 2,77 1,74 7,14 8,10
Net Profit (Loss)1 9,68 -0,04 1,49 9,72 -10,72 24,91 35,00
Net-Margin6 1,44 -0,01 0,22 1,38 -1,47 3,33 4,50
Cashflow1,7 69,59 118,69 81,97 34,64 78,00 50,57 74,00
Earnings per share8 0,20 -0,19 0,03 0,20 -0,23 0,52 0,74
Dividend per share8 0,05 0,00 0,00 0,00 0,00 0,04 0,04
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Mediclin
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
659510 DE0006595101 AG 179,55 Mio € 06.12.2000 Kaufen 8FW9FWGV+63
* * *
PE 2026e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
5,82 17,70 0,33 17,10 0,73 2,23 0,24
Dividends
Dividend '2023
in €
Dividend '2024
in €
Dividend '2025e
in €
Div.-Yield '2025e
in %
0,00 0,04 0,04 1,06%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
28.06.2026 04.05.2026 30.07.2026 04.11.2025 27.03.2026
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
+0,00%
3,78 €
ATH 15,02 €
+12,80% +22,77% +56,20% +52,42% -65,64%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2025          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2025 by Gereon Kruse #BGFL